Your browser doesn't support javascript.
loading
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.
Patnaik, Akash; Swanson, Kenneth D; Csizmadia, Eva; Solanki, Aniruddh; Landon-Brace, Natalie; Gehring, Marina P; Helenius, Katja; Olson, Brian M; Pyzer, Athalia R; Wang, Lily C; Elemento, Olivier; Novak, Jesse; Thornley, Thomas B; Asara, John M; Montaser, Laleh; Timmons, Joshua J; Morgan, Todd M; Wang, Yugang; Levantini, Elena; Clohessy, John G; Kelly, Kathleen; Pandolfi, Pier Paolo; Rosenblatt, Jacalyn M; Avigan, David E; Ye, Huihui; Karp, Jeffrey M; Signoretti, Sabina; Balk, Steven P; Cantley, Lewis C.
Afiliación
  • Patnaik A; Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Dana Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts. apatnaik1@uchicago.edu.
  • Swanson KD; Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Csizmadia E; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
  • Solanki A; The University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
  • Landon-Brace N; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Gehring MP; Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Helenius K; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Olson BM; Harvard Stem Cell Institute, Boston, Massachusetts.
  • Pyzer AR; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Wang LC; Harvard Stem Cell Institute, Boston, Massachusetts.
  • Elemento O; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Novak J; Laboratório de Farmacologia Aplicada, PUCRS, Porto Alegre, Brazil.
  • Thornley TB; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Asara JM; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
  • Montaser L; The University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
  • Timmons JJ; Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Dana Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Morgan TM; Meyer Cancer Center, Weill Cornell Medical College, New York, New York.
  • Wang Y; Meyer Cancer Center, Weill Cornell Medical College, New York, New York.
  • Levantini E; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Clohessy JG; Transplant Institute and Immunology Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Kelly K; Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Pandolfi PP; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Rosenblatt JM; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Avigan DE; Department of Urology, University of Michigan, Ann Arbor, Michigan.
  • Ye H; Department of Urology, University of Michigan, Ann Arbor, Michigan.
  • Karp JM; Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Dana Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Signoretti S; Harvard Stem Cell Institute, Boston, Massachusetts.
  • Balk SP; Institute of Biomedical Technologies, National Research Council (CNR), Pisa, Italy.
  • Cantley LC; Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 7(7): 750-765, 2017 07.
Article en En | MEDLINE | ID: mdl-28274958
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Piridinas / Proteína p53 Supresora de Tumor / Proteína HMGB1 / Fosfohidrolasa PTEN / Quimiocina CXCL12 / Anilidas Límite: Animals / Humans / Male Idioma: En Revista: Cancer Discov Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Piridinas / Proteína p53 Supresora de Tumor / Proteína HMGB1 / Fosfohidrolasa PTEN / Quimiocina CXCL12 / Anilidas Límite: Animals / Humans / Male Idioma: En Revista: Cancer Discov Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos